Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft

NCT05316701 is registered in ClinicalTrials.gov with Orca Biosystems, Inc. as lead sponsor.

NCT NCT05316701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05316701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Lead sponsor
Orca Biosystems, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 21, 2022
Completion date
July 31, 2026
Enrollment
187 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoid leukemia, acute myeloid leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome, therapy-related myelodysplastic syndrome, undifferentiated leukemia